Header Logo

Connection

RICHARD ERIC DAVIS to Leukemia, Myeloid, Acute

Back to Details
This is a "connection" page, showing publications RICHARD ERIC DAVIS has written about Leukemia, Myeloid, Acute.
RICHARD ERIC DAVIS
Connection Strength
0.124
Leukemia, Myeloid, Acute
  1. Antileukemia activity of the novel peptidic CXCR4 antagonist LY2510924 as monotherapy and in combination with chemotherapy. Blood. 2015 Jul 09; 126(2):222-32.
    View in: PubMed
    Score: 0.033
  2. XIAP downregulation promotes caspase-dependent inhibition of proteasome activity in AML cells. Leuk Res. 2013 Aug; 37(8):974-9.
    View in: PubMed
    Score: 0.028
  3. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013 May 16; 121(20):4166-74.
    View in: PubMed
    Score: 0.028
  4. Effect of long-term storage in TRIzol on microarray-based gene expression profiling. Cancer Epidemiol Biomarkers Prev. 2010 Oct; 19(10):2445-52.
    View in: PubMed
    Score: 0.024
  5. Treatment of poor prognosis AML patients using PSC833 (valspodar) plus mitoxantrone, etoposide, and cytarabine (PSC-MEC). Adv Exp Med Biol. 1999; 457:47-56.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.